Treatment - Page 9 of 471 Posts on Medivizor

Comparing the long-term outcomes of percutaneous coronary intervention with everolimus-eluting stents versus coronary artery bypass grafting in patients with mutltivessel coronary artery disease.

Posted by Medivizor on Mar 26, 2023 in Coronary artery disease | 0 comments

In a nutshell This study compared the long-term outcomes of percutaneous coronary intervention (PCI) using everolimus (Afinitor)-eluting stents (Xience) versus coronary artery bypass grafting (CABG) in patients with multivessel coronary artery disease (CAD). The data showed that both treatments were associated with a similar risk of heart attack, stroke,...

Comparing the effects of acupuncture combined with metformin versus metformin alone on pregnancy rate in women with polycystic ovary syndrome.

Posted by Medivizor on Mar 26, 2023 in Infertility | 0 comments

In a nutshell This study evaluated the effects of acupuncture combined with metformin (Glucophage) versus metformin alone on pregnancy rate in women with polycystic ovary syndrome (PCOS). The data showed that acupuncture combined with metformin improved the pregnancy rate, ovulation rate, and insulin resistance compared with metformin treatment alone in...

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Posted by Medivizor on Mar 26, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated which sequence of treatment should be given first – immunotherapy or targeted therapy – for the most clinical benefit in patients with BRAF-mutated metastatic melanoma. The data showed that immunotherapy followed by targeted therapy significantly improved survival outcomes in these patients. Some background...

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Posted by Medivizor on Mar 26, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) given before surgery for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that atezolizumab given before surgery was safe and effective for patients with NSCLC. Some background Non-small cell lung cancer (NSCLC)...

Evaluating the effectiveness and safety of high-dose rosuvastatin combined with telmisartan or amlodipine on glucose metabolism in hypertensive patients with impaired fasting glucose.

Posted by Medivizor on Mar 26, 2023 in Hypertension | 0 comments

In a nutshell This study evaluated the effectiveness and safety of high-dose rosuvastatin (Crestor) combined with telmisartan (Micardis) or amlodipine (Norvasc) on glucose metabolism in patients with atherosclerotic cardiovascular disease (ASCVD), hypertension (high blood pressure), and impaired fasting glucose (IFG or prediabetes). The...

Evaluating the effectiveness and safety of busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for patients with adult B-cell acute lymphoblastic leukemia.

Posted by Medivizor on Mar 26, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of busulfan (Bu; Busulfex) plus cyclophosphamide (Cy; Cytoxan) (BuCy) regimen versus total body irradiation (TBI) plus cyclophosphamide (TBI-Cy) regimen for patients with adult B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission undergoing allogeneic hematopoietic...

Comparing darolutamide, apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Posted by Medivizor on Mar 26, 2023 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness of darolutamide (Nubeqa), apalutamide (Erleada), and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that darolutamide, apalutamide, and enzalutamide were similarly effective and improved survival outcomes compared to placebo...

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Posted by Medivizor on Mar 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak...

Evaluating the effectiveness and safety of oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Posted by Medivizor on Mar 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of oral paclitaxel (Taxol) plus encequidar (HM 30181) versus intravenous (IV) paclitaxel in patients with metastatic breast cancer (BC). This study concluded that oral paclitaxel plus encequidar was more effective than IV paclitaxel with manageable side effects in these...

Evaluating the safety and effectiveness of different doses of asundexian in patients with acute myocardial infarction treated with dual antiplatelet therapy.

Posted by Medivizor on Mar 16, 2023 in Coronary artery disease | 0 comments

In a nutshell This study investigated the safety and effectiveness of different doses of asundexian (BAY 2433334) in patients with acute myocardial infarction (MI; heart attack) treated with dual antiplatelet therapy (DAPT). The data showed that asundexian 50 mg when added to DAPT inhibits blood clotting factor XIa by more than 90% without...

Evaluating the safety and effectiveness of ibrutinib lead-in treatment before venetoclax initiation in reducing tumor size in patients with chronic lymphocytic leukemia.

Posted by Medivizor on Mar 16, 2023 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) lead-in treatment before venetoclax (Venclexta) initiation for reducing tumor size in patients with chronic lymphocytic leukemia (CLL). The data showed that three cycles of ibrutinib lead-in treatment before venetoclax initiation significantly reduced the tumor...

Is real time glucose monitoring better than intermittent scanning for patients with type 1 diabetes?

Posted by Medivizor on Mar 5, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study compared intermittent scanning continuous glucose monitoring (isCGM) with real-time continuous glucose monitoring (rtCGM) for the treatment of type 1 diabetes (T1D). It found that compared to isCGM, rt CGM resulted in increased time spent in range and improved blood glucose control in these patients. Some background...

Treatment Posts on Medivizor

Comparing the long-term outcomes of percutaneous coronary intervention with everolimus-eluting stents versus coronary artery bypass grafting in patients with mutltivessel coronary artery disease.

Comparing the effects of acupuncture combined with metformin versus metformin alone on pregnancy rate in women with polycystic ovary syndrome.

Which sequence of treatment should be given first- immunotherapy or targeted therapy for patients with BRAF-mutated metastatic melanoma?

Evaluating the effectiveness and safety outcomes of atezolizumab given before surgery in patients with non-small cell lung cancer.

Evaluating the effectiveness and safety of high-dose rosuvastatin combined with telmisartan or amlodipine on glucose metabolism in hypertensive patients with impaired fasting glucose.

Evaluating the effectiveness and safety of busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for patients with adult B-cell acute lymphoblastic leukemia.

Comparing darolutamide, apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Evaluating the effectiveness and safety of oral paclitaxel plus encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Evaluating the safety and effectiveness of different doses of asundexian in patients with acute myocardial infarction treated with dual antiplatelet therapy.

Evaluating the safety and effectiveness of ibrutinib lead-in treatment before venetoclax initiation in reducing tumor size in patients with chronic lymphocytic leukemia.

Is real time glucose monitoring better than intermittent scanning for patients with type 1 diabetes?

Categories

Recent Posts

Archives

Treatment Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email